LAMIVUDINE TEVA PHARMA B.V. 300 mg, film-coated tablet 30 tablets, CIP 3400938244861
Active ingredients: Lamivudine
Commercialized according to BDPMDispensing in France: Prescription only
Film-coated tablet30 tablets, CIP 3400938244861orale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- LAMIVUDINE TEVA PHARMA B.V. 300 mg, comprimé pelliculé
- Pharmaceutical form
- comprimé pelliculé
- Route of administration
- orale
- Presentation description
- pilulier(s) polyéthylène haute densité (PEHD) avec fermeture de sécurité enfant de 30 comprimé(s)
- Marketing authorisation holder
- TEVA (PAYS-BAS)
- Reimbursement according to BDPM
- 100%
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 30 Nov 2021
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Initial prescription by a hospital doctor
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
61785366CIP73824486CIP133400938244861Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| LAMIVUDINEcomprimé | 300 mg · un comprimé | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Other packages of this medicine
The same medicine in another pack size, according to BDPM.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.